Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

The Importance of Age in Selecting a Testing Strategy for Stable Symptomatic Patients With Suspected Coronary Artery Disease.

Journal of the American Geriatrics Society·2026
Same author

Choosing Between CABG and PCI for 3-Vessel Coronary Disease: What's Cost Got to Do With It?

Journal of the American College of Cardiology·2026
Same author

Additive prognostic value of functional performance to coronary artery anatomy: the ISCHEMIA trial.

European heart journal. Cardiovascular Imaging·2026
Same author

Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease.

Journal of the American College of Cardiology·2025
Same author

Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.

Circulation·2025
Same author

Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease: Long-Term Follow-Up of the PROMISE Randomized Clinical Trial.

JAMA cardiology·2025

相关实验视频

Updated: May 22, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

心力衰竭中血栓栓塞的风险:来自心力衰竭试验中的突然心脏死亡 (SCD-HeFT) 的分析.

Ronald S Freudenberger1, Anne S Hellkamp, Jonathan L Halperin

  • 1Department of Medicine, Robert Wood Johnson Medical School, Suite 6100, 125 Paterson St, New Brunswick, NJ 08903, USA. r.freudenberger@yahoo.com

Circulation
|May 9, 2007
PubMed
概括

在没有心房的心力衰竭患者中,阿米奥达龙或ICD与安慰剂相比降低了血栓栓塞的风险. 高血压和较低的射出分数独立预测了这些事件.

更多相关视频

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

相关实验视频

Last Updated: May 22, 2026

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease
12:15

Tissue Preparation Techniques for Contrast-Enhanced Micro Computed Tomography Imaging of Large Mammalian Cardiac Models with Chronic Disease

Published on: February 8, 2022

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

科学领域:

  • 心脏病学 心脏病学
  • 血管医学 血管医学
  • 临床试验 临床试验

背景情况:

  • 心力衰竭患者面临明显的中风风险 (每年1.3-3.5%).
  • 关于心力衰竭患者没有心房动的血栓栓塞发病率和风险因素的数据有限.
  • 心力衰竭中的突然心脏死亡试验 (SCD-HeFT) 招募了2521名中度心力衰竭患者.

研究的目的:

  • 在没有心房动的心力衰竭患者中确定血栓栓塞的发生率.
  • 为了确定血栓栓塞的预测因素,包括左心室喷射分数.
  • 评估阿米奥达龙和植入式心脏转换器-除器 (ICD) 对血栓塞栓风险的影响.

主要方法:

  • 对2114名没有心房动病史的SCD-HeFT参与者的分析.
  • 平均随访时间为45.5个月.
  • 多变量分析以确定血栓栓塞的预测因子和治疗效应.

主要成果:

  • 血栓栓塞的4年发生率为4.0% (每年1.7%).
  • 阿米奥达龙 (2.6%) 和ICD (3.2%) 的血栓栓塞率低于安慰剂 (6.0%).
  • 高血压和左心室喷射率降低是血栓栓塞的独立预测因素.

结论:

  • 没有心房动的心力衰竭患者每年有1.7%的血栓栓塞率.
  • 与安慰剂相比,阿米奥达龙和ICD显著降低了血栓栓塞的风险.
  • 基线高血压和较低的射出分数是这一群体中血栓栓塞的关键风险因素.